-
Je něco špatně v tomto záznamu ?
Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin
H. Hefter, D. Rosenthal, A. Jansen, R. Brauns, B. Ürer, H. Bigalke, HP. Hartung, SG. Meuth, JI. Lee, P. Albrecht, S. Samadzadeh
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-04-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-04-01 do Před 1 rokem
- MeSH
- botulotoxiny typu A * MeSH
- myši MeSH
- nervosvalové látky * MeSH
- neutralizující protilátky MeSH
- průřezové studie MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: For many indications, BoNT/A is repetitively injected with the risk of developing neutralizing antibodies (NABs). Therefore, it is important to analyze whether there is a difference in antigenicity between the different licensed BoNT/A preparations. METHODS: In this cross-sectional study, the prevalence of NABs was tested by means of the sensitive mouse hemidiaphragm assay (MHDA) in 645 patients. Patients were split into those having exclusively been treated with the complex protein-free incoBoNT/A preparation (CF-MON group) and those having started BoNT/A therapy with a complex protein-containing BoNT/A preparation (CC-I group). This CC-I group was split into those patients who remained either on abo- or onaBoNT/A (CC-MON group) and those who had been treated with at least two BoNT/A preparations (CC-SWI group). To balance treatment duration, only CC-MON patients who did not start their BoNT/A therapy more than 10 years before recruitment (CC-MON-10 group) were further analyzed. The log-rank test was used to compare the prevalence of NABs in the CF-MON and CC-MON-10 group. RESULTS: In the CF-MON subgroup, no patient developed NABs. In the CC-I group, 84 patients were NAB-positive. NABs were found in 33.3% of those who switched preparations (CC-SWI) and in 5.9% of the CC-MON-10 group. Kaplan-Meier curves for remaining NAB-negative under continuous BoNT/A therapy were significantly different (p < 0.035) between the CF-MON and CC-MON-10 group. CONCLUSION: Frequent injections of a complex protein-containing BoNT/A preparation are associated with significantly higher risks of developing NABs than injections with the same frequency using the complex protein-free incoBoNT/A preparation.
Brain and Mind Center University of Sydney Sydney Australia
Department of Neurology Medical University of Vienna Vienna Austria
Department of Neurology Palacky University Olomouc Olomouc Czech Republic
Institute of Toxicology Medical School Hannover Hannover Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004432
- 003
- CZ-PrNML
- 005
- 20230425141402.0
- 007
- ta
- 008
- 230418s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00415-022-11395-2 $2 doi
- 035 __
- $a (PubMed)36195775
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Hefter, Harald $u Department of Neurology, Medical Faculty, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany. harald.hefter@online.de $1 https://orcid.org/0000000310697684
- 245 10
- $a Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin / $c H. Hefter, D. Rosenthal, A. Jansen, R. Brauns, B. Ürer, H. Bigalke, HP. Hartung, SG. Meuth, JI. Lee, P. Albrecht, S. Samadzadeh
- 520 9_
- $a BACKGROUND: For many indications, BoNT/A is repetitively injected with the risk of developing neutralizing antibodies (NABs). Therefore, it is important to analyze whether there is a difference in antigenicity between the different licensed BoNT/A preparations. METHODS: In this cross-sectional study, the prevalence of NABs was tested by means of the sensitive mouse hemidiaphragm assay (MHDA) in 645 patients. Patients were split into those having exclusively been treated with the complex protein-free incoBoNT/A preparation (CF-MON group) and those having started BoNT/A therapy with a complex protein-containing BoNT/A preparation (CC-I group). This CC-I group was split into those patients who remained either on abo- or onaBoNT/A (CC-MON group) and those who had been treated with at least two BoNT/A preparations (CC-SWI group). To balance treatment duration, only CC-MON patients who did not start their BoNT/A therapy more than 10 years before recruitment (CC-MON-10 group) were further analyzed. The log-rank test was used to compare the prevalence of NABs in the CF-MON and CC-MON-10 group. RESULTS: In the CF-MON subgroup, no patient developed NABs. In the CC-I group, 84 patients were NAB-positive. NABs were found in 33.3% of those who switched preparations (CC-SWI) and in 5.9% of the CC-MON-10 group. Kaplan-Meier curves for remaining NAB-negative under continuous BoNT/A therapy were significantly different (p < 0.035) between the CF-MON and CC-MON-10 group. CONCLUSION: Frequent injections of a complex protein-containing BoNT/A preparation are associated with significantly higher risks of developing NABs than injections with the same frequency using the complex protein-free incoBoNT/A preparation.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 12
- $a nervosvalové látky $7 D009465
- 650 _2
- $a průřezové studie $7 D003430
- 650 12
- $a botulotoxiny typu A $7 D019274
- 650 _2
- $a neutralizující protilátky $7 D057134
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rosenthal, Dietmar $u Department of Neurology, Medical Faculty, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany
- 700 1_
- $a Jansen, Alexander $u Department of Neurology, Medical Faculty, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany
- 700 1_
- $a Brauns, Raphaela $u Department of Neurology, Medical Faculty, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany
- 700 1_
- $a Ürer, Beyza $u Department of Neurology, Medical Faculty, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany
- 700 1_
- $a Bigalke, Hans $u Institute of Toxicology, Medical School Hannover, Hannover, Germany
- 700 1_
- $a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany $u Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic $u Brain and Mind Center, University of Sydney, Sydney, Australia $u Department of Neurology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Meuth, Sven G $u Department of Neurology, Medical Faculty, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany
- 700 1_
- $a Lee, John-Ih $u Department of Neurology, Medical Faculty, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany
- 700 1_
- $a Albrecht, Philipp $u Department of Neurology, Medical Faculty, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany
- 700 1_
- $a Samadzadeh, Sara $u Department of Neurology, Medical Faculty, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany $u Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- 773 0_
- $w MED00002835 $t Journal of neurology $x 1432-1459 $g Roč. 270, č. 2 (2023), s. 788-796
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36195775 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141358 $b ABA008
- 999 __
- $a ok $b bmc $g 1924863 $s 1190641
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 270 $c 2 $d 788-796 $e 20221005 $i 1432-1459 $m Journal of neurology $n J Neurol $x MED00002835
- LZP __
- $a Pubmed-20230418
